Surveillance in achalasia is fraught with controversies and varied clinical practice. There is an absence of an established guideline from experts from either side of the Atlantic and the idea of achalasia surveillance comes from anecdotal experience, case reports and retrospective studies with low numbers.

Through this survey, we aim to observe clinical practice with regards to achalasia surveillance. Furthermore, we aim to put forward an argument for a nation-wide study and the creation of a database that would allow us to collect data on both retrospective and prospective cases and management and incidence of malignancy, to provide robust evidence on surveillance need and strategy.

Establishing current practice in the UK will enable a more realistic overview of whether surveillance in this small group of patients is worthwhile in terms of cost effectiveness and the overall impact on long-term survival.

As most clinicians will have only a small number of patients under their care, establishing a national database might be considered worthwhile to determine more accurately the risk involved and other predisposing factors.

On behalf of the BSG and AUGIS,

Dr Rohit Sinha
Mr Andrew Wayman
Prof Mike Bramble